{"abstract":"This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following Patents and Patent Applications and all continuing U.S. and foreign patents/ patent applications to Sangamo BioSciences, Inc. located in Richmond, California, USA:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/09/07/2016-21366.html","cfr_references":[],"citation":"81 FR 61704","comment_url":null,"comments_close_on":"2016-09-22","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 22, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-21366","effective_on":null,"end_page":61704,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/09/07/2016-21366.xml","html_url":"https://www.federalregister.gov/documents/2016/09/07/2016-21366/prospective-grant-of-exclusive-patent-license-the-development-of-an-anti-cd19-chimeric-antigen","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-21366?publication_date=2016-09-07","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-09-07/2016-21366/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":866,"last_updated":"2026-06-27 18:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-09-07/pdf/2016-21366.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-21366.pdf?1473165930","publication_date":"2016-09-07","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/09/07/2016-21366.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T21:01:46Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":61704,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: The Development of an Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment of Human Cancers","toc_doc":"Development of Anti-CD19 Chimeric Antigen Receptor for Treatment of Human Cancers","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":81}